Drug Approval News: Johnson & Johnson (J&J) has received approvals from both the European Commission (EC) and US Food and Drug Administration (FDA) for its tuberculosis (TB) treatment, Sirturo (bedaquiline, TMC207, R207910). Its mechanism of action is inhibition of mycobacterial ATP synthesis. It has also been shown to inhibit SARS-CoV-2 main protease (3CLpro), giving bedaquiline potential as a repurposed COVID therapeutic.
For Postdoc
Customers!
Website Created by Advanta Advertising LLC.
